Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metabolism

Background:

• Beta-catenin (β-catenin) gene mutations are common in hepatocellular carcinoma (HCC).
• While β-catenin's oncogenic role is known, its impact on HCC tumor metabolism and autophagy remains unclear.
• Understanding these pathways is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of β-catenin in regulating hepatocellular carcinoma cell metabolism.
• To elucidate the relationship between β-catenin, glutamine synthetase, and autophagy.
• To determine the impact of β-catenin activity on sorafenib sensitivity in HCC.

Main Methods:

• Analysis of β-catenin activity in HCC cell lines (Hep3B, HepG2).
• Assessment of glutamine synthetase expression and its effect on autophagy.
• Gene silencing of glutamine synthetase.
• Evaluation of cellular sensitivity to sorafenib.

Main Results:

• β-Catenin activation upregulates glutamine synthetase, inducing autophagy in HCC cells.
• Autophagy in β-catenin-active HCC cells is dependent on glutamine synthetase.
• β-Catenin-active HCC cells exhibit increased sensitivity to sorafenib compared to β-catenin wild-type cells.
• Glutamine synthetase-mediated autophagy explains the observed sorafenib sensitivity.

Conclusions:

• Beta-catenin plays a key role in regulating HCC cell metabolism through glutamine synthetase and autophagy.
• This pathway is critical for the heightened sensitivity of β-catenin-active HCC cells to sorafenib.
• Targeting glutamine metabolism and autophagy presents a potential therapeutic strategy for HCC.